Biomira's re-worked cancer vaccine looks as safe as ever
19th Nov 2005, 05:48 GMT
Interim results from a study conducted by the biotechnology firm Biomira have shown that a new formulation of its cancer therapy, BLP25 Liposome Vaccine, does not differ from the previous version in terms of safety but may be easier to manufacturer.
Biomira's re-worked cancer vaccine looks as safe as ever related news:
- Biomira's Phase 2 Lung Cancer Vaccine Trial Shows No Safety Concerns — Medical News Today RSS/XML Feed
- Scottish women, who have high incidence of cervical cancer, given vaccine — The Cancer Blog
- Melanoma vaccine — MedTerms Word of the Day
- Scots teenagers first to test cervical cancer vaccine — Scotsman.com News
- Killing regulatory T cells boosts effectiveness of cancer vaccine — EurekAlert! - Medicine and Health
- Scots Teenagers Are First to Test Cervical Cancer Vaccine — RedOrbit News - Health
- Novel pancreatic cancer vaccine nudging survival rates higher — Medical News Today RSS/XML Feed
- 1st Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma — Neurology News from StratCenter.com
- Cancer vaccine promising — baltimoresun.com - nation/world
- Women Recalled for Cancer Check — RedOrbit News - Health
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol